Stroke treatment with tenecteplase via artery
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests a clot-busting drug called tenecteplase given directly into the brain artery for people having a moderate stroke caused by a blockage in a medium-sized blood vessel. The goal is to see if it helps improve recovery when given within 24 hours of stroke symptoms starting.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You had no significant disability before the stroke (could do daily activities on your own).
- You can receive treatment within 24 hours of when symptoms began.
- Your stroke symptoms are moderate to severe, or mild but disabling (like trouble using your hand, speaking, or seeing).
- A brain scan shows a blockage in a medium-sized artery and the damaged area is small enough.
- You have no bleeding in the brain, active bleeding risk, or major health problems that would make the treatment unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new clot-busting medicine called tenecteplase, given directly into the blood vessel in the brain, to treat strokes caused by a blockage in a medium-sized artery. The goal is to see if it can help restore blood flow and reduce disability, especially for patients who can be treated within 24 hours of stroke onset.
This trial tests whether giving a clot-busting drug called tenecteplase directly into the brain artery after a successful mechanical clot removal can improve recovery for people with a certain type of stroke. The goal is to see if it safely helps clear any remaining tiny clots and reduces disability.
This trial looks at giving a clot-busting medicine directly into the brain arteries (intra-arterial TNK) when a stroke procedure (thrombectomy) doesn’t reopen the blocked vessel enough. It aims to improve recovery by improving blood flow while checking for safety, especially bleeding risk.
This trial tests if a clot-busting drug called tenecteplase can improve outcomes for people with a large vessel stroke when treatment starts 4.5 to 24 hours after symptoms began, and when a mechanical clot removal procedure (EVT) is not available. You would receive tenecteplase or standard medical care to see which works better.
This trial tests if giving a second dose of the clot-busting drug tenecteplase can help people whose stroke symptoms don't improve after the first dose, when a large or medium artery in the brain is still blocked. It may be an option for patients who cannot have a mechanical clot removal procedure.
This trial tests a clot-busting drug for people who had a stroke but don't know when it started, like waking up with symptoms. It may help reduce disability if given soon after noticing symptoms.
Hear when a new Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.